Highlights  MuSK is a receptor tyrosine kinase crucial for formation of neuromuscular junctions  Activation of MuSK requires Agrin-induced Lrp4 binding and recruitment of Dok-7  MuSK kinase activity has to be tightly regulated for proper signaling  MuSK mutations and autoantibodies obstruct signaling causing muscle disorders  MuSK function has been implicated in ALS treatment Abstract The receptor tyrosine kinase MuSK (muscle-specific kinase) is the key signaling molecule during the formation of a mature and functional neuromuscular junction (NMJ). Signal transduction events downstream of MuSK activation induce both pre-and postsynaptic differentiation, which, most prominently, includes the clustering of acetylcholine receptors (AChRs) at synaptic sites. MuSK activation requires a complex interplay between its coreceptor Lrp4 (low-density lipoprotein receptor-related protein-4), the motor neuron-derived heparan-sulfate proteoglycan Agrin and the intracellular adaptor protein Dok-7. A tight regulation of MuSK kinase activity is crucial for proper NMJ development. Defects in MuSK signaling are the cause of muscle weakness as reported in congenital myasthenic syndromes and myasthenia gravis. This review focuses on recent structure-based analyses of MuSK, Agrin, Lrp4 and Dok-7 interactions and their function during MuSK activation. Conclusions about the regulation of
MuSK originally described as Trk-related receptor tyrosine kinase (RTK) in the electric organ of Torpedo californica [46] , was isolated as a novel RTK from denervated mouse muscle and termed muscle-specific kinase due to its prominent expression in skeletal muscle [100] .
MuSK is weakly expressed in proliferating myoblasts but strongly induced upon differentiation into myotubes [100] . Of note, recently it was shown that MuSK acts as coreceptor of bone morphogenic proteins in myoblasts to stimulate the expression of a distinct set of genes linking MuSK to pathways involved in muscle differentiation and growth [112] .
MuSK mRNA is expressed in synaptic nuclei of the endplate and MuSK protein is specifically localized to the postsynaptic muscle membrane [100] . Subsequently MuSK was also found in other tissues including the brain, liver and lung as well as liver cancer cell lines.
Very few studies have addressed its role outside of the skeletal muscle but findings have implicated MuSK in memory consolidation and liver carcinogenesis [11, 24, 26, 45] .
MuSK activation, kinase activity and subsequent downstream signaling has been extensively studied during NMJ formation as well as maintenance. Elaborate and detailed reviews on MuSK-dependent signaling pathways are available [60, 108] , I will therefore focus on the most recent developments and will try to reconcile these with previous data and models.
MuSK structure and activation

The MuSK ectodomain
The extracellular domain of MuSK carries three Ig-like domains and one cysteine-rich domain (CRD), also termed Frizzled (FZ)-like domain (Fig. 1A) . MuSK in vertebrates excluding mammals holds a Kringle domain between the CRD and the single transmembrane helix. Structural and genetic studies have revealed detailed information on the role of the different domains. Most notably, the Ig1 domain is involved in MuSK homodimerization and Lrp4 binding [91, 116] . Especially, a solvent-exposed region around I96 is critical for Lrp4 binding (Fig. 1B ). Lrp4 and MuSK are pre-assembled in the absence of Agrin but activation of MuSK is induced only in the presence of Agrin, which forms a tetrameric complex with Lrp4 [120] . Agrin binding to Lrp4 increases MuSK-Lrp4 interaction by a yet unknown mechanism. Current models implicate either a new surface formed by the tetrameric agrin-Lrp4 complex or conformational changes in Lrp4, which would foster MuSK binding and activation [116, 120] . Interaction with Lrp4 presumably brings the hydrophobic faces of Ig1 (region containing L83) into a position that favors MuSK dimerization to facilitate trans-phosphorylation and activation of the kinase domains [116] . The CRD is not required for Agrin-induced MuSK activation but was shown to mediate Wnt-induced MuSK activation and AChR clustering in cultured muscle cells as well as muscle prepatterning in Zebrafish [31, 114, 118] . The MuSK CRD is able to bind Wnt proteins in vitro but in muscle cells Wnt requires Lrp4 for MuSK activation and AChR clustering [92, 114] . 
The MuSK cytoplasmic region
The cytoplasmic region is characterized by a short juxtamembrane region, a tyrosine kinase domain followed by an 8 amino-acid C-terminal sequence. A crystal structure of the unphosphorylated MuSK intracellular region revealed a principal architectural structure common to other RTKs [97] . The kinase domain is comprised of an N-terminal lobe with a five-stranded  sheet and one  helix, and a C-terminal lobe, predominantly made of  helices. The N-terminal lobe carries residues essential for ATP binding and the C-terminal lobe holds the activation loop with the critical residues Y750, Y754 and Y755 and the catalytic loop ( Fig. 1C ). Mutation of Y750, Y754 and Y755 in the activation loop inhibit MuSK activation as does the mutation of K608 in 3 of the C-terminal lobe [28, 36, 118] . The Nterminal juxtamembrane region forms a short  helix proximal to the kinase core with the remaining residues disordered. Y553 located in the disordered sequence of in the juxtamembrane region represents a major phosphorylation site and lies within an NPYX motif [97, 102] . Upon phosphorylation of Y553, Dok-7, an adaptor protein that contains pleckstrin homology (PH) and phosphotyrosine-binding (PTB) domains is recruited to the NPXY motif [77] . Mutation of Y553 associated with a lack of autophosphorylation disturbs Agrin-dependent MuSK activation and interferes with Dok-7 binding (discussed below) [36, 77] . The short C-terminal region, which contains a putative PDZ binding motif is dispensable for MuSK function although it is presumably accessible for protein binding since the sequence is disordered in the crystal structure [118] .
MuSK activation
J o u r n a l P r e -p r o o f Although, MuSK presents features similar to many other RTKs, its mode of activation is distinct from all known RTKs. Foremost, MuSK requires three other proteins for full activation: Agrin, derived from motor neurons, Lrp4, localized at the muscle membrane and Dok-7, expressed in the cytoplasm of myofibers ( Fig. 2A ). The C-terminal LG3 domain of Agrin was shown to bind to the first -propeller domain of Lrp4, fostered by the splice insert (8, 11 or 19 amino acids), which is present in the neuronal-specific forms of Agrin [116, 120] .
Agrin-Lrp4 dimers further assemble into tetramers via three additional interdimer interfaces.
Tetramerization is a prerequisite for MuSK activation [120] . As described above isoleucine 96 in the MuSK Ig1 is required for binding to Lrp4 via the LDLa domains 6-8, the first two EGF-like domains, and the first of four -propeller domains [97, 116] . MuSK-Lrp4 interaction is increased by Agrin by a yet unknown mechanism but APP and APP-like proteins have been implicated as additional modulatory components, which are able to bind Agrin and Lrp4 simultaneously [15, 116] . shown that Dok-7 lacking the C-terminal region including the SH2 motifs was able to rescue neonatal lethality by partially restoring MuSK activation and NMJ formation [98] . Further, myasthenia patients homozygous for the most prevalent DOK7 mutation, 1124_1127dupTGCC, which results in a Dok-7 protein lacking the SH2 target motifs, have impaired yet active NMJs [3, 89] .
A stringent autoinhibition involving the juxtamembrane and the autoactivation loop is thought to be important for restricting MuSK activity to the synaptic site. A distinct autoinhibition mechanism involves the juxtamembrane region, which is largely disordered in MuSK and does not interact with the kinase domain [97] . Y553 is in the juxtamembrane region recruits binding [36, 77] . The crystal structure of unphosphorylated MuSK implied that the activation loop of MuSK provides a particular strong autoinhibition (4 times stronger than in the insulin receptor) [97] . Autoinhibition by the activation loop is a common mechanism among RTKs to control kinase activation [41, 59] . Studies on the insulin receptor have demonstrated that phosphorylation of the activation loop tyrosines results in destabilization of the autoinhibitory conformation and stabilization of the active conformation [40] . Full kinase activation represents a multi-step process with a specific order of autophosphorylation. Y754 in MuSK is the first tyrosine in the activation loop to become phosphorylated [97] . Structural analysis of the insulin-like growth factor 1 receptor kinase and insulin receptor using an ATPcompetitive small-molecule inhibitor indicated that E1159 (S751 in MuSK) and R1164 (K756 in MuSK) in the insulin receptor form a salt bridge, which appears to position Y1162 (Y754 in MuSK) in the active site for trans-phosphorylation [109] . In that respect, the recently reported phosphorylation of S751 in the activation loop might support Y754 positioning in the active site for trans-phosphorylation since phosphorylation of tyrosines, serines and threonines positively affects hydrogen bonding to donors such as arginine or lysine [8] . Sustaining Y754 phosphorylation is expected to relief autoinhibition and/or to stabilize kinase activity.
Taken together, MuSK's mode of activation is attributed to the requirement of temporally and spatially restricted signaling events such as stringent autoinhibition to prevent activation in the absence of Agrin and activation via Agrin and Lrp4 to localize activation to the synaptic site.
MuSK function during development
Prepatterning
Prepatterning was first described around 20 years ago proposing that also the muscle has an instructive role during NMJ formation [61, 110, 111] . This initially controversial finding is in the central region of the muscle. Indeed, it was shown that high expression of MuSK is sufficient to prepattern AChR clusters [50] . Interestingly, calcium influx is required for prepatterning and for restricting MuSK expression to the central domain of muscle fibers providing a mechanism that would prevent MuSK activation and AChR clustering in the peripheral regions of myofibers [12, 48] . Of note, the mechanisms regulating prepatterning have changed during vertebrate evolution. Whereas Lrp4 is required for prepatterning in mice, it is obsolete for prepatterning in Zebrafish [82] . In contrast, MuSK is essential both in mice and Zebrafish. In Zebrafish prepatterning is regulated by the MuSK CRD domain as well as Wnt4 and Wnt11r [31] . These data suggest that the Wnt-dependent activation of MuSK during early development was replaced by a Lrp4-dependent mechanism during vertebrate evolution.
NMJ Formation, Maturation and Maintenance
Upon innervation MuSK is activated by the heparansulfate proteoglycan Agrin [29] . Agrin is produced by motor neurons and deposited in the basal lamina of the synaptic cleft [67] .
Agrin does not bind MuSK directly but interacts with Lrp4, a member of the LDL receptor family [51, 115] . Upon binding, the Lrp4/MuSK complex presumably undergoes a structural rearrangement that leads to dimerization and subsequent autophosporylation of MuSK (see above 
Aging and MuSK associated diseases
Aging of NMJs
During aging a reduction in AChR density, NMJ fragmentation and denervation have been reported [99] . The mechanisms that cause NMJ decline in aging organisms are not well understood but one would assume that maintaining NMJ function at later stages also depends on Agrin/Lrp4/MuSK signaling. Consistent with this and also mentioned above, loss of AChRs, NMJ fragmentation and disassembly were observed in adult mice lacking Agrin, [94, 106] . Eighteen different MUSKmutations have been published to date (Fig. 2B) , which share some of the clinical features of DOK7-CMS such as predominant limb-girdle weakness [79] . Most of the identified mutations are located either in the Ig1 domain (4 out of 18) or the kinase domain (9 out of 18).
Functional studies on some of the mutations in the kinase domain have been reported to affect MuSK kinase activity demonstrating that a tight control of kinase activity is crucial for NMJ function [4, 13, 14, 64, 83] . Mutations P344R and C317R in the CRD domain are the only extracellular mutations examined functionally and both interfere with MuSK trafficking and protein stability [71, 83] . More than half of the missense mutations still await further characterization, so far leaving questions about the underlying pathophysiology open.
Analyzing these mutations will aid to our understanding of MuSK activation and function and also help to design therapeutics and therapeutic strategies for CMS patients. This is of particular importance, since MuSK CMS patients are often unresponsive to classical treatments such as anticholinesterase inhibitors or even present worsening of symptoms when treated with such. Ephedrine, a sympathomimetic amine, is the most efficient therapy but its mode of action at the NMJ remains largely unclear [16, 57] .
Myasthenia gravis
Myasthenia gravis (MG) is an autoimmune disease caused by autoantibodies targeting key molecules of the NMJ, such as AChR, MuSK and Lrp4 [53] . MG is characterized by altered tissue architecture, diminished densities and/or functionality of AChRs and reduced neuromuscular transmission leading to severe fatigable skeletal muscle weakness. The majority of MG patients present autoantibodies against AChRs but a small group of patients develop antibodies against MuSK [38] . Patients with MuSK MG do not show thymic abnormalities and no apparent clinical benefit of thymectomy [58] . MuSK MG patients are also more severely affected with more frequent myasthenic crises [21, 22, 32, 56] .
MuSK antibodies belong to the IgG4 subclass which differ in their Fc region and are therefore unable to activate the classical complement system or immune cells [52, 66] . In addition, IgG4 can generate bi-specific, or functionally monovalent autoantibodies, as a consequence of Fab-arm exchange. These autoantibodies are unable to cross-link homogeneous antigens eliminating antigenic modulation as underlying pathomechanism [54] . MuSK antibodies bind predominantly to the first Ig-like domain, thereby block Lrp4-MuSK interaction and consequently MuSK signaling causing a decrease in AChR density at the NMJ and consequently impaired neuromuscular transmission [43, 44, 52, 66, 78, 93] . A small fraction of antibodies in MuSK MG patients are of IgG1-3 type. These however do not affect MuSK-Lrp4 interaction, nevertheless are still able to reduce AChR clustering in cultured myotubes suggesting a distinct pathogenic mechanism [52] . In MuSK MG patients and animal models, also presynaptic abnormalities were observed including a reduced quantal release of ACh suggesting that MuSK antibodies might affect retrograde signaling to motor neurons [73] [74] [87, 101] [75]. The mechanism is unknown but disruption of Lrp4-MuSK interaction might be involved since Lrp4 acts as retrograde signal from the muscle to the motor neuron [107, 113] .
Amyotrophic lateral sclerosis
Amyotrophic lateral sclerosis (ALS) is a neurogenerative disease caused by motor neuron death leading to paralysis and fatal respiratory failure within a few years of diagnosis [34, 96] . Death of motor neurons has been considered as the primary underlying pathomechanism but more recent studies have shown that loss of NMJs precedes loss of motor neurons [23, 81, 86] . First indications that preservation of NMJ function would represent a potential therapeutic strategy came from studies using overexpression of MuSK in the SOD-G93A ALS mouse model [80] . Increasing MuSK expression stabilized NMJs, reduced denervation and improved motor function but failed to extend life expectancy. function or life span [9, 88] . These findings can be explained by differences in approaches J o u r n a l P r e -p r o o f and methods to evaluate functional aspects but future studies are required to clarify the therapeutic potential of boosting MuSK activity.
Unresolved aspects of MuSK function and future prospects
Spatially confined MuSK signaling is thought to be critical for restricting instructive signals to the synaptic site. Several mechanisms have been put forward, including increased autoinhibition of the MuSK kinase activity and spatially controlled activation by Agrin. In addition, MuSK protein becomes specifically enriched and localized to the postsynaptic muscle membrane providing a primary scaffold for AChR clustering and NMJ formation [50, 100] . One way of enrichment is synapse-specific expression of MuSK, which is thought to be regulated by specific promoter elements such as an N-Box, an E-box and a cyclic AMP response element -like motif [49, 68, 95] . However, MuSK expressed throughout the muscle by muscle-specific promoters such as MCK (muscle creatine kinase) is also specifically aggregated at synaptic sites suggesting that mechanisms exist that regulate MuSK trafficking [35, 47, 50] . How this specific localization is achieved is currently unclear. Two possible ways of accumulation can be envisioned: (1) Taken together, MuSK is a unique RTK with a distinct mode of activation and represents a central regulator of NMJ development. Much is known about MuSK function but significant gaps remain. Future studies are required to close these gaps to fully understand the action of MuSK and to be in a position to design novel therapeutic strategies against neuromuscular disorders.
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